^
    Back
    Association details:
    Biomarker:EGFRvIII mutation
    Cancer:Glioblastoma
    Drug:erlotinib (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

    Excerpt:
    ...- EGFRvIII mutation detected on pretreatment tissue from at least 1 prior surgery....
    Trial ID:
    NCT01257594
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    J Clin Oncol
    Title:

    Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

    Excerpt:
    For PFS, the presence of EGFRvIII mutant was correlated with poor survival in the erlotinib arm (P = .003)...
    DOI:
    10.1200/JCO.2008.17.5984
    Trial ID:
    NCT00086879